In Western countries, mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are the most identified driver mutation in non-squamous NSCLC, presenting in approximately 30% of adenocarcinoma cases [8]. This evidence concerns the gene KRAS and adenocarcinoma.